Annex Advisory Services LLC Boosts Holdings in Globus Medical, Inc. $GMED

Key Points

• Annex Advisory Services increased its Globus Medical stake by 6.4% in the second quarter, bringing its holdings to 372,794 shares valued at approximately $29.5 million. Institutional investors collectively own 95.16% of the company.
• Globus Medical reported quarterly EPS of $1.34, beating estimates of $1.10, while revenue reached $789.61 million and rose 5.9% year over year. The company maintained fiscal 2026 EPS guidance of $4.95–$5.05.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $101.77, despite several firms recently lowering targets. GMED shares opened at $85.13, down 1.2%.

Annex Advisory Services LLC lifted its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 6.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 372,794 shares of the medical device company's stock after buying an additional 22,407 shares during the period. Annex Advisory Services LLC owned approximately 0.27% of Globus Medical worth $29,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Elevation Wealth Partners LLC increased its stake in Globus Medical by 2,178.6% during the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company's stock worth $25,000 after acquiring an additional 305 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company's stock valued at $29,000 after purchasing an additional 167 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC grew its holdings in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after purchasing an additional 197 shares during the period. Finally, Larson Financial Group LLC increased its position in shares of Globus Medical by 83.4% during the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company's stock worth $46,000 after purchasing an additional 242 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company's stock.

Globus Medical Stock Down 1.2%

Shares of GMED opened at $85.13 on Wednesday. The company has a market cap of $11.56 billion, a P/E ratio of 21.77, a PEG ratio of 1.39 and a beta of 0.95. Globus Medical, Inc. has a fifty-two week low of $54.15 and a fifty-two week high of $101.40. The firm's 50 day moving average price is $79.59 and its 200 day moving average price is $85.06.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.10 by $0.24. The company had revenue of $789.61 million during the quarter, compared to analysts' expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm's revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Research analysts forecast that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on GMED. Zacks Research cut shares of Globus Medical from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research report on Monday, July 13th. BMO Capital Markets initiated coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They issued an "outperform" rating and a $94.00 price target on the stock. Wells Fargo & Company decreased their price objective on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Finally, Royal Bank Of Canada lowered their price objective on shares of Globus Medical from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $101.77.

Insider Activity

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 18.38% of the company's stock.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source